Xellar secures fresh funding to advance AI-driven drug research
By Li Jing | chinadaily.com.cn | Updated: 2026-11-19 15:10
Xellar Biosystems has secured tens of millions of yuan in strategic financing to expand an artificial intelligence platform designed to improve early-stage drug testing, the biotechnology startup announced on Wednesday.
The investors include a Shanghai State-backed investment company and a pharmaceutical investment fund linked to Chinese drugmaker CSPC Pharmaceutical Group. Xellar did not disclose the exact amount raised or its valuation.
The funding will support its 3D Bio Intelligence platform, which combines organ-on-a-chip technology, three-dimensional cell imaging and automated experiments with AI analysis to study how drugs affect human tissues.
Organ-on-a-chip technology uses human cells grown in miniature devices to reproduce some features of organs. Such models can help researchers study drug effectiveness and potential safety risks before clinical trials.
Unlike basic two-dimensional cell cultures, the devices can incorporate multiple cell types and physical conditions, giving researchers more detailed information about how human tissues respond to drugs, according to the company.
Xellar said its platform collects data from biological experiments and uses AI to identify patterns in drug responses and guide further testing. The company aims to train computational models using repeated cycles of experiments and analysis.
Xellar sought to "make complex biological processes more quantifiable, understandable and predictable", said Xin Xie, the company's co-founder and chief executive officer, adding that the financing would help scale up the platform and strengthen its AI capabilities.
The Shanghai investor said it would use its networks in life sciences and AI to support Xellar's development. The pharmaceutical fund said it would help the company connect with industry resources.
The latest financing follows $50 million in Series A and A+ funding announced in June. Xellar is based in Boston and lists offices in Shanghai, Zhengzhou in Henan province and Shenzhen in Guangdong province on its website.
Xellar also plans to explore virtual cells, organs and patients to simulate complex biological processes, but gave no timetable for commercial applications.





















